Home > Drugs A – Z > Ezetimibe (By mouth)

Ezetimibe (By mouth)

Lowers high cholesterol levels.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Ezetimibe is used to lower cholesterol and triglyceride (fat-like substances) levels in the blood. Using this medicine may help prevent medical problems caused by such substances clogging the blood vessels. This medicine is available only with your doctor's prescription… Read more
Brand names include
Zetia
Drug classes About this
Antihyperlipidemic
Combinations including this drug

What works? Research summarized

Evidence reviews

Ezetimibe for hypercholesterolaemia: Executive summary of final report A10-02, Version 1.0

The aim of this investigation is the benefit assessment of treatment with ezetimibe (in mono- or combination therapy) compared to treatment with placebo or other lipid-lowering drugs, as well as to non-drug treatment options in patients with hypercholesterolaemia. The focus of the assessment was on patient-relevant outcomes.

Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation

To review the evidence for the clinical and cost-effectiveness of ezetimibe (in its licensed indication) as combination therapy or monotherapy for the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia in the UK.

Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease

This guideline updates for primary prevention, the NICE technology appraisal, ‘Statins for the prevention of cardiovascular events’ (TA94, 2007) and reviews and updates the recommendations made in the NICE guideline Lipid Modification (CG67, 2008) for primary and secondary prevention of cardiovascular disease (CVD). The scope for this guideline was limited to the identification and assessment of CVD risk and to the assessment and modification of lipids in people at risk of CVD, or people with known CVD. The guideline development group wishes to make clear that lipid modification should take place as part of a programme of risk reduction which also include attention to the management of all other known CVD risk factors.

See all (36)

Summaries for consumers

Comparing Statins and Combination Drugs

How do statins and combination drugs compare in lowering "bad" cholesterol (LDL-c)?

PCSK9 inhibitors for prevention of cardiovascular disease

Describe the effectiveness and safety of PCSK9 inhibitors for cardiovascular disease prevention.

Lipid‐lowering agents for nephrotic syndrome

Nephrotic syndrome is a relatively rare disease in which the kidneys leak protein into the urine. A common early sign is swelling in the feet and face. Other signs and symptoms of nephrotic syndrome include low levels of protein in the blood, and high levels of fats in the blood, particularly cholesterol and triglycerides.

PubMed Health Blog...

read all...